155 related articles for article (PubMed ID: 33466381)
1. Does Antibody Stabilize the Ligand Binding in GP120 of HIV-1 Envelope Protein? Evidence from MD Simulation.
Yadav S; Pandey V; Kumar Tiwari R; Ojha RP; Dubey KD
Molecules; 2021 Jan; 26(1):. PubMed ID: 33466381
[TBL] [Abstract][Full Text] [Related]
2. Thermodynamics of binding of a low-molecular-weight CD4 mimetic to HIV-1 gp120.
Schön A; Madani N; Klein JC; Hubicki A; Ng D; Yang X; Smith AB; Sodroski J; Freire E
Biochemistry; 2006 Sep; 45(36):10973-80. PubMed ID: 16953583
[TBL] [Abstract][Full Text] [Related]
3. Enhanced dynamics of HIV gp120 glycoprotein by small molecule binding.
Shrivastava I; LaLonde JM
Biochemistry; 2011 May; 50(19):4173-83. PubMed ID: 21488663
[TBL] [Abstract][Full Text] [Related]
4. Binding mode characterization of NBD series CD4-mimetic HIV-1 entry inhibitors by X-ray structure and resistance study.
Curreli F; Kwon YD; Zhang H; Yang Y; Scacalossi D; Kwong PD; Debnath AK
Antimicrob Agents Chemother; 2014 Sep; 58(9):5478-91. PubMed ID: 25001301
[TBL] [Abstract][Full Text] [Related]
5. Naturally occurring variability in the envelope glycoprotein of HIV-1 and development of cell entry inhibitors.
Brower ET; Schön A; Freire E
Biochemistry; 2010 Mar; 49(11):2359-67. PubMed ID: 20166763
[TBL] [Abstract][Full Text] [Related]
6. Conformational and structural features of HIV-1 gp120 underlying the dual receptor antagonism by cross-reactive neutralizing antibody m18.
Gift SK; Zentner IJ; Schön A; McFadden K; Umashankara M; Rajagopal S; Contarino M; Duffy C; Courter JR; Zhang MY; Gershoni JM; Cocklin S; Dimitrov DS; Smith AB; Freire E; Chaiken IM
Biochemistry; 2011 Apr; 50(14):2756-68. PubMed ID: 21351734
[TBL] [Abstract][Full Text] [Related]
7. Altered Env conformational dynamics as a mechanism of resistance to peptide-triazole HIV-1 inactivators.
Zhang S; Holmes AP; Dick A; Rashad AA; Enríquez Rodríguez L; Canziani GA; Root MJ; Chaiken IM
Retrovirology; 2021 Oct; 18(1):31. PubMed ID: 34627310
[TBL] [Abstract][Full Text] [Related]
8. Activation and Inactivation of Primary Human Immunodeficiency Virus Envelope Glycoprotein Trimers by CD4-Mimetic Compounds.
Madani N; Princiotto AM; Zhao C; Jahanbakhshsefidi F; Mertens M; Herschhorn A; Melillo B; Smith AB; Sodroski J
J Virol; 2017 Feb; 91(3):. PubMed ID: 27881646
[TBL] [Abstract][Full Text] [Related]
9. In Silico Identification of Novel Aromatic Compounds as Potential HIV-1 Entry Inhibitors Mimicking Cellular Receptor CD4.
Andrianov AM; Nikolaev GI; Kornoushenko YV; Xu W; Jiang S; Tuzikov AV
Viruses; 2019 Aug; 11(8):. PubMed ID: 31412617
[TBL] [Abstract][Full Text] [Related]
10. Effects of CD4 Binding on Conformational Dynamics, Molecular Motions, and Thermodynamics of HIV-1 gp120.
Li Y; Deng L; Yang LQ; Sang P; Liu SQ
Int J Mol Sci; 2019 Jan; 20(2):. PubMed ID: 30634692
[TBL] [Abstract][Full Text] [Related]
11. Enhanced exposure of human immunodeficiency virus type 1 primary isolate neutralization epitopes through binding of CD4 mimetic compounds.
Yoshimura K; Harada S; Shibata J; Hatada M; Yamada Y; Ochiai C; Tamamura H; Matsushita S
J Virol; 2010 Aug; 84(15):7558-68. PubMed ID: 20504942
[TBL] [Abstract][Full Text] [Related]
12. Insight derived from molecular dynamics simulations into molecular motions, thermodynamics and kinetics of HIV-1 gp120.
Sang P; Yang LQ; Ji XL; Fu YX; Liu SQ
PLoS One; 2014; 9(8):e104714. PubMed ID: 25105502
[TBL] [Abstract][Full Text] [Related]
13. Structure-based design, synthesis and validation of CD4-mimetic small molecule inhibitors of HIV-1 entry: conversion of a viral entry agonist to an antagonist.
Courter JR; Madani N; Sodroski J; Schön A; Freire E; Kwong PD; Hendrickson WA; Chaiken IM; LaLonde JM; Smith AB
Acc Chem Res; 2014 Apr; 47(4):1228-37. PubMed ID: 24502450
[TBL] [Abstract][Full Text] [Related]
14. Structure-Based Design of a Small Molecule CD4-Antagonist with Broad Spectrum Anti-HIV-1 Activity.
Curreli F; Kwon YD; Zhang H; Scacalossi D; Belov DS; Tikhonov AA; Andreev IA; Altieri A; Kurkin AV; Kwong PD; Debnath AK
J Med Chem; 2015 Sep; 58(17):6909-6927. PubMed ID: 26301736
[TBL] [Abstract][Full Text] [Related]
15. Characterization of Human Immunodeficiency Virus (HIV-1) Envelope Glycoprotein Variants Selected for Resistance to a CD4-Mimetic Compound.
Anang S; Richard J; Bourassa C; Goyette G; Chiu TJ; Chen HC; Smith AB; Madani N; Finzi A; Sodroski J
J Virol; 2022 Sep; 96(17):e0063622. PubMed ID: 35980207
[TBL] [Abstract][Full Text] [Related]
16. Molecular dynamics simulations reveal distinct differences in conformational dynamics and thermodynamics between the unliganded and CD4-bound states of HIV-1 gp120.
Li Y; Deng L; Liang J; Dong GH; Xia YL; Fu YX; Liu SQ
Phys Chem Chem Phys; 2020 Mar; 22(10):5548-5560. PubMed ID: 32119016
[TBL] [Abstract][Full Text] [Related]
17. HIV gp120 H375 is unique to HIV-1 subtype CRF01_AE and confers strong resistance to the entry inhibitor BMS-599793, a candidate microbicide drug.
Schader SM; Colby-Germinario SP; Quashie PK; Oliveira M; Ibanescu RI; Moisi D; Mespléde T; Wainberg MA
Antimicrob Agents Chemother; 2012 Aug; 56(8):4257-67. PubMed ID: 22615295
[TBL] [Abstract][Full Text] [Related]
18. Structural plasticity and conformational transitions of HIV envelope glycoprotein gp120.
Korkut A; Hendrickson WA
PLoS One; 2012; 7(12):e52170. PubMed ID: 23300605
[TBL] [Abstract][Full Text] [Related]
19. Computational discovery of novel HIV-1 entry inhibitors based on potent and broad neutralizing antibody VRC01.
Andrianov AM; Kashyn IA; Tuzikov AV
J Mol Graph Model; 2015 Sep; 61():262-71. PubMed ID: 26298811
[TBL] [Abstract][Full Text] [Related]
20. A model of peptide triazole entry inhibitor binding to HIV-1 gp120 and the mechanism of bridging sheet disruption.
Emileh A; Tuzer F; Yeh H; Umashankara M; Moreira DR; Lalonde JM; Bewley CA; Abrams CF; Chaiken IM
Biochemistry; 2013 Apr; 52(13):2245-61. PubMed ID: 23470147
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
